


# Medications for Opioid Use Disorder (MOUD)

## References

1. Sullivan, M. A., Bisaga, A., Pavlicova, M., Carpenter, K. M., Choi, C. J., Mishlen, K., Levin, F. R., Mariani, J. J., & Nunes, E. V. (2019). A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. *American Journal of Psychiatry*, 176(2), 129-137.
2. Substance Abuse and Mental Health Services Administration. (2021). *Medications for Opioid Use Disorder*. Treatment Improvement Protocol (TIP) Series 63. Publication N. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration.
3. Substance Abuse and Mental Health Services Administration. (2024). *42 CFR part 8 final rule - frequently asked questions*. Substance Abuse and Mental Health Services Administration. Retrieved February 26, 2025, from <https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8/faqs>
4. Cunningham, C., Edlund, M. J., Fishman, M., Gordon, A. J., Jones, H. E., Langleben, D., & Femino, J. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. *J Addict Med*, 14(2S Suppl 1), 1-91.
5. Lim, J., Farhat, I., Douros, A., & Panagiotoglou, D. (2022). Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials. *PLoS One*, 17(3), e0266142.
6. Zhang, P., Tossone, K., Ashmead, R., Bickert, T., Bailey, E., Doogan, N. J., Mack, A., Schmidt, S., & Bonny, A. E. (2022). Examining differences in retention on medication for opioid use disorder: an analysis of Ohio Medicaid data. *Journal of Substance Abuse Treatment*, 136, 108686.
7. Wakeman, S. E., Larochele, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Network Open*, 3(2), e1920622-e1920622.
8. Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Jr, Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., Gordon, M., Fishman, M., Chen, D. T., Bonnie, R. J., Cornish, J. W., Murphy, S. M., & O'Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*, 374(13), 1232-1242.
9. Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ (Clinical Research Ed.)*, 357, j1550.
10. Kelty, E., Joyce, D., & Hulse, G. (2019). A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine. *The American Journal of Drug and Alcohol Abuse*, 45(3), 285-291.
11. Ma, J., Bao, Y. P., Wang, R. J., Su, M. F., Liu, M. X., Li, J. Q., Degenhardt, L., Farrell, M., Blow, F. C., Ilgen, M., Shi, J., & Lu, L. (2019). Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. *Molecular Psychiatry*, 24(12), 1868-1883.
12. Larochele, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. *Annals of Internal Medicine*, 169(3), 137-145.
13. Santo, T., Jr, Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., Chen, A., Tran, L. T., Bharat, C., Padmanathan, P., Cousins, G., Dupouy, J., Kelty, E., Muga, R., Nosyk, B., Min, J., Pavarin, R., Farrell, M., & Degenhardt, L. (2021). Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. *JAMA Psychiatry*, 78(9), 979-993.
14. Lier, A. J., Seval, N., Vander Wyk, B., Di Paola, A., & Springer, S. A. (2022). Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. *Journal of Substance Abuse Treatment*, 142, 108852.
15. Fanucchi, L., Springer, S. A., & Korthuis, P. T. (2019). Medications for treatment of opioid use disorder among persons living with HIV. *Current HIV/AIDS Reports*, 16(1), 1-6.
16. Socias, M. E., Cui, Z., Le Foll, B., Lei, J., Stewart, S., Anand, R., & Jutras-Aswad, D. (2024). Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial. *HIV Medicine*, 25(7), 817-825.
17. Liao, S., Jang, S., Tharp, J. A., & Lester, N. A. (2023). Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset. *Journal of Substance Use and Addiction Treatment*, 154, 209139.
18. Gopaldas, M., Wenzel, K., Campbell, A. N. C., Jalali, A., Fishman, M., Rotrosen, J., Nunes, E. V., & Murphy, S. M. (2023). Impact of medication-based treatment on health care utilization among individuals with opioid use disorder. *Psychiatric Services*, 74(12), 1227-1233.

19. Jalali, A., Ryan, D. A., Jeng, P. J., McCollister, K. E., Leff, J. A., Lee, J. D., Nunes, E. V., Novo, P., Rotrosen, J., Schackman, B. R., & Murphy, S. M. (2020). Health-related quality of life and opioid use disorder pharmacotherapy: a secondary analysis of a clinical trial. *Drug and Alcohol Dependence*, 215, 108221.
20. Latif, Z. E., Šaltyte Benth, J., Solli, K. K., Opheim, A., Kunoe, N., Krajci, P., Sharma-Haase, K., & Tanum, L. (2019). Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study. *JAMA Psychiatry*, 76(2), 127-134.
21. Zaaier, E. R., van Dijk, L., de Bruin, K., Goudriaan, A. E., Lammers, L. A., Koeter, M. W., van den Brink, W., & Booij, J. (2015). Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. *Psychopharmacology*, 232(14), 2597-2607.
22. Moazen-Zadeh, E., Ziafat, K., Yazdani, K., Kamel, M. M., Wong, J. S. H., Modabbernia, A., Blanken, P., Verthein, U., Schütz, C. G., Jang, K., Akhondzadeh, S., & Krausz, R. M. (2021). Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials. *The American Journal of Drug and Alcohol Abuse*, 47(3), 280-304.
23. Watts, B. V., Gottlieb, D. J., Riblet, N. B., Gui, J., & Shiner, B. (2022). Association of medication treatment for opioid use disorder with suicide mortality. *American Journal of Psychiatry*, 179(4), 298-304.
24. Bahji, A., Carlone, D., & Altomare, J. (2020). Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. *Addiction*, 115(8), 1413-1425.
25. Soares, W. E., 3rd, Wilson, D., Gordon, M. S., Lee, J. D., Nunes, E. V., O'Brien, C. P., Shroff, M., & Friedmann, P. D. (2019). Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. *Drug and Alcohol Dependence*, 194, 482-486.
26. Molero, Y., Zetterqvist, J., Binswanger, I. A., Hellner, C., Larsson, H., & Fazel, S. (2018). Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses and crime. *American Journal of Psychiatry*, 175(10), 970-978.
27. Paschen-Wolff, M., Greenfield, S. F., Kathryn McHugh, R., Burlew, K., Pavlicova, M., Choo, T. H., Barbosa-Leiker, C., Ruglass, L. M., Mennenga, S., Rotrosen, J., Nunes, E. V., & Campbell, A. N. C. (2023). Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder. *The American Journal on Addictions*, 32(6), 584-592.
28. Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010). Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. *Drug and Alcohol Dependence*, 106(1), 56-60.
29. Dever, J. A., Hertz, M. F., Dunlap, L. J., Richardson, J. S., Wolicki, S. B., Biggers, B. B., Edlund, M. J., Bohm, M. K., Turcios, D., Jiang, X., Zhou, H., Evans, M. E., & Guy, G. P., Jr. (2024). The medications for opioid use disorder study: methods and initial outcomes from an 18-month study of patients in treatment for opioid use disorder. *Public Health Reports*, 139(4), 484-493.
30. Golan, O. K., Totaram, R., Perry, E., Fortson, K., Rivera-Atilano, R., Entress, R., Golan, M., Andraka-Christou, B., Whitaker, D., & Pigott, T. (2022). Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. *Drug and Alcohol Dependence*, 235, 109445.
31. Maremmani, I., Pani, P. P., Pacini, M., & Perugi, G. (2007). Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. *Journal of Substance Abuse Treatment*, 33(1), 91-98.
32. Tanum, L., Solli, K. K., Benth, J. Š., Opheim, A., Sharma-Haase, K., Krajci, P., & Kunøe, N. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. *JAMA Psychiatry*, 74(12), 1197-1205.
33. Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*, (3).
34. Bell, J., & Strang, J. (2020). Medication treatment of opioid use disorder. *Biological Psychiatry*, 87(1), 82-88.
35. Baxley, C., Borsari, B., Reavis, J. V., Manuel, J. K., Herbst, E., Becker, W., Pennington, D., Batki, S. L., & Seal, K. (2023). Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: a systematic review of randomized controlled trials. *Addictive Behaviors*, 139, 107589.
36. Xu, K. Y., Presnall, N., Mintz, C. M., Borodovsky, J. T., Bhat, N. R., Bierut, L. J., & Gruzca, R. A. (2021). Association of opioid use disorder treatment with alcohol-related acute events. *JAMA Network Open*, 4(2), e210061.
37. Xu, K. Y., Mintz, C. M., Presnall, N., Bierut, L. J., & Gruzca, R. A. (2022). Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder and cooccurring polysubstance use. *JAMA Network Open*, 5(5), e2211363.
38. Thornton, P. (reviewer). (2024). *Naltrexone side effects*. Drugs.com. Retrieved February 26, 2025, from <https://www.drugs.com/sfx/naltrexone-side-effects.html>
39. Thornton, P. (reviewer). (2024). *Buprenorphine side effects*. Drugs.com. Retrieved February 26, 2025, from <https://www.drugs.com/sfx/buprenorphine-side-effects.html>
40. Thornton, P. (reviewer). (2024). *Methadone side effects*. Drugs.com. Retrieved February 26, 2025, from <https://www.drugs.com/sfx/methadone-side-effects.html>
41. Trammel, C. J., Whitley, J., & Kelly, J. C. (2024). Pharmacotherapy for opioid use disorder in pregnancy. *Current Opinion in Obstetrics & Gynecology*, 36(2), 74-80.



These references support our MOUD at-a-glance poster and booklet.

Visit our website to obtain a list of cited references, to order copies of this printed poster and to download a free PDF of the poster, companion booklet and other MOUD-related tools.

[case.edu/socialwork/centerforebp/ohio-sud-coe/resource-library/tools-for-practitioners](https://case.edu/socialwork/centerforebp/ohio-sud-coe/resource-library/tools-for-practitioners)